MA49126A - Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 - Google Patents

Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2

Info

Publication number
MA49126A
MA49126A MA049126A MA49126A MA49126A MA 49126 A MA49126 A MA 49126A MA 049126 A MA049126 A MA 049126A MA 49126 A MA49126 A MA 49126A MA 49126 A MA49126 A MA 49126A
Authority
MA
Morocco
Prior art keywords
modulators
derivatives used
phenyl derivatives
pge2 receptors
pge2
Prior art date
Application number
MA049126A
Other languages
English (en)
Other versions
MA49126B1 (fr
Inventor
Christoph Boss
Olivier Corminboeuf
Heinz Fretz
Isabelle Lyothier
Davide Pozzi
Sylvia Richard-Bildstein
Hervé Siendt
Thierry Sifferlen
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA49126A publication Critical patent/MA49126A/fr
Publication of MA49126B1 publication Critical patent/MA49126B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MA49126A 2017-05-18 2018-05-17 Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 MA49126B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017062031 2017-05-18
PCT/EP2018/062862 WO2018210994A1 (fr) 2017-05-18 2018-05-17 Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2

Publications (2)

Publication Number Publication Date
MA49126A true MA49126A (fr) 2020-03-25
MA49126B1 MA49126B1 (fr) 2021-10-29

Family

ID=62186480

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49126A MA49126B1 (fr) 2017-05-18 2018-05-17 Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2

Country Status (32)

Country Link
US (1) US11712438B2 (fr)
EP (1) EP3625222B1 (fr)
JP (1) JP7159214B2 (fr)
KR (1) KR102632028B1 (fr)
CN (1) CN110612296A (fr)
AR (1) AR111941A1 (fr)
AU (1) AU2018269666B2 (fr)
BR (1) BR112019024109A2 (fr)
CA (1) CA3060597A1 (fr)
CL (1) CL2019003275A1 (fr)
CO (1) CO2019010578A2 (fr)
CR (1) CR20190559A (fr)
CY (1) CY1124608T1 (fr)
DK (1) DK3625222T3 (fr)
EA (1) EA201992676A1 (fr)
ES (1) ES2893452T3 (fr)
HR (1) HRP20211533T1 (fr)
HU (1) HUE056080T2 (fr)
IL (1) IL270623B2 (fr)
LT (1) LT3625222T (fr)
MA (1) MA49126B1 (fr)
MX (1) MX388256B (fr)
PE (1) PE20191814A1 (fr)
PH (1) PH12019502563A1 (fr)
PL (1) PL3625222T3 (fr)
PT (1) PT3625222T (fr)
RS (1) RS62440B1 (fr)
SG (1) SG11201908729UA (fr)
SI (1) SI3625222T1 (fr)
TW (1) TWI765041B (fr)
UA (1) UA125123C2 (fr)
WO (1) WO2018210994A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3625223B1 (fr) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3124353A1 (fr) * 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Composes inhibiteurs de kinase, compositions et methodes d'utilisation
EP4245301A4 (fr) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. Traitement du cancer par utilisation combinée d'un antagoniste d'ep4 et d'un inhibiteur de point de contrôle immunitaire
WO2022272062A1 (fr) 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Composés antagonistes d'ep2
WO2025229177A1 (fr) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Formes cristallines d'un dérivé d'indole n-substitué

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
JP2003528144A (ja) 2000-03-24 2003-09-24 ファーマジーン ラボラトリーズ リミテッド 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
JP2005532291A (ja) 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
AU2003216579A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
US20040023853A1 (en) 2002-05-23 2004-02-05 Peri Krishna G. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
CN100408570C (zh) 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
EP1661897B1 (fr) 2003-08-26 2013-12-04 Teijin Pharma Limited Derive de pyrrolopyrimidinone
RS20060143A (sr) 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
EP1678147B1 (fr) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CN1950334A (zh) 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
JP4054368B2 (ja) 2004-05-04 2008-02-27 ファイザー株式会社 置換メチルアリール又はヘテロアリールアミド化合物
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten
WO2006128129A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Traitement anticancereux
AR060403A1 (es) 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
CA2648729A1 (fr) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Derives d'indolamide comme antagonistes du recepteur ep4
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
BRPI0714409A2 (pt) 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
CA2660133C (fr) 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Derives de thiophenecarboxamide en tant que ligands du recepteur ep4
WO2008039882A1 (fr) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2
US8158671B2 (en) 2007-02-26 2012-04-17 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
JP2010522218A (ja) 2007-03-26 2010-07-01 メルク フロスト カナダ リミテツド Ｅｐ４受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体
MX2009010297A (es) 2007-03-26 2009-10-12 Astellas Pharma Inc Derivado de ornitina.
EP2014657A1 (fr) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine en tant que modulateurs du récepteur EP2
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
CA2702008A1 (fr) 2007-10-12 2009-04-16 Ingenium Pharmaceuticals Gmbh Inhibiteurs de proteine kinases
US8598202B2 (en) 2008-02-19 2013-12-03 Janssen Pharmaceutica Nv Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
EP2320906B1 (fr) 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Dérivés d amides hétérocycliques en tant qu antagonistes du récepteur ep4
CN102164942B (zh) 2008-09-19 2017-02-15 生物科技研究有限公司 三萜系化合物及其使用的方法
CN102224154A (zh) 2008-09-25 2011-10-19 默克弗罗斯特加拿大有限公司 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
EP2504008A1 (fr) 2009-11-23 2012-10-03 Lexicon Pharmaceuticals, Inc. Procédés et essais pour le traitement du syndrome du côlon irritable
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
PH12013500467A1 (en) 2010-09-21 2013-04-29 Eisai R&D Man Co Ltd Pharmaceutical composition
JP5273689B2 (ja) 2010-09-29 2013-08-28 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
EA201390717A1 (ru) 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
WO2012066065A1 (fr) 2010-11-17 2012-05-24 Novartis Ag Composés phényl-hétéroaryl amine et leurs utilisations
CA2820109C (fr) 2010-12-10 2018-01-09 Rottapharm S.P.A. Derives de pyridinamide en tant qu'antagonistes de recepteur ep4
WO2012103071A2 (fr) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Composés et compositions
CA2830129C (fr) 2011-03-24 2016-07-19 Chemilia Ab Nouveaux derives de pyrimidine
EP2702043A1 (fr) 2011-04-29 2014-03-05 Exelixis, Inc. Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase
US9518044B2 (en) 2011-06-20 2016-12-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
US9181279B2 (en) 2011-07-04 2015-11-10 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor antagonists
EP2554662A1 (fr) 2011-08-05 2013-02-06 M Maria Pia Cosma Procédés pour le traitement de maladies rétiniennes dégénératives
WO2013090552A1 (fr) 2011-12-13 2013-06-20 Yale University Compositions et procédés pour la réduction de l'épuisement de ctl
IN2014KN02601A (fr) * 2012-04-24 2015-05-08 Vertex Pharma
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
EP2711364A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl ou benzimidazolyl)amino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
CA2888338C (fr) 2012-11-27 2021-07-20 Thomas Helledays Stiftelse For Medicinsk Forskning Inhibiteurs mth1 pour le traitement du cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (fr) 2013-02-07 2014-08-13 Almirall, S.A. Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
HUE036649T2 (hu) 2013-05-30 2018-07-30 Idorsia Pharmaceuticals Ltd CXCR7 receptor modulátorok
PT3009426T (pt) 2013-06-12 2018-06-08 Kaken Pharma Co Ltd Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo
EA029901B1 (ru) 2013-09-04 2018-05-31 Бристол-Майерс Сквибб Компани Соединения для применения в качестве иммуномодуляторов
CU24362B1 (es) 2013-09-06 2018-10-04 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
WO2015044900A1 (fr) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Composés immunomodulateurs thérapeutiques
WO2015058031A1 (fr) 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Inhibiteurs d'adn-pk
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
EA028921B1 (ru) 2013-12-17 2018-01-31 Эли Лилли Энд Компани Феноксиэтилы
DK3083554T3 (da) 2013-12-17 2019-05-13 Lilly Co Eli Dimethylbenzoesyreforbindelser
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US10052332B2 (en) 2014-04-29 2018-08-21 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
US20170182003A1 (en) 2014-05-23 2017-06-29 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
RU2016151390A (ru) 2014-06-04 2018-07-17 Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг Ингибиторы мтн1 для лечения воспалительных и аутоиммунных заболеваний
PE20170268A1 (es) 2014-06-19 2017-04-21 Ariad Pharma Inc Compuestos de heteroarilo para la inhibicion de cinasa
WO2016021742A1 (fr) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr4
TWI739666B (zh) 2015-01-09 2021-09-11 日商小野藥品工業股份有限公司 醫藥組成物
EP3325490B1 (fr) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited DÉRIVÉS DE 1,2,3,4-TÉTRAHYDRO-1,7-NAPHTYRIDIN-8-AMINE SUBSTITUÉS EN POSITION 1
ET LEUR UTILISATION EN TANT QU ANTAGONISTES DU RÉCEPTEUR EP4
MX390051B (es) 2015-10-16 2025-03-20 Eisai R&D Man Co Ltd Antagonistas de ep4.
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AU2017295720B2 (en) 2016-07-13 2021-07-22 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
EP3625223B1 (fr) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
US20200069686A1 (en) 2017-05-18 2020-03-05 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives

Also Published As

Publication number Publication date
PE20191814A1 (es) 2019-12-27
JP2020520356A (ja) 2020-07-09
MA49126B1 (fr) 2021-10-29
DK3625222T3 (da) 2021-10-25
CR20190559A (es) 2020-02-10
WO2018210994A1 (fr) 2018-11-22
IL270623B (en) 2022-11-01
HUE056080T2 (hu) 2022-01-28
IL270623B2 (en) 2023-03-01
PL3625222T3 (pl) 2021-12-27
TWI765041B (zh) 2022-05-21
AR111941A1 (es) 2019-09-04
AU2018269666A1 (en) 2020-01-16
CY1124608T1 (el) 2022-07-22
CA3060597A1 (fr) 2018-11-22
MX388256B (es) 2025-03-19
US11712438B2 (en) 2023-08-01
CN110612296A (zh) 2019-12-24
BR112019024109A2 (pt) 2020-06-02
KR102632028B1 (ko) 2024-01-31
IL270623A (fr) 2019-12-31
EP3625222A1 (fr) 2020-03-25
PH12019502563A1 (en) 2020-07-20
ES2893452T3 (es) 2022-02-09
SI3625222T1 (sl) 2021-11-30
UA125123C2 (uk) 2022-01-12
KR20200010352A (ko) 2020-01-30
CL2019003275A1 (es) 2020-05-04
EP3625222B1 (fr) 2021-07-21
AU2018269666B2 (en) 2022-02-03
MX2019013718A (es) 2020-01-30
PT3625222T (pt) 2021-10-07
RS62440B1 (sr) 2021-11-30
US20200179383A1 (en) 2020-06-11
TW201900175A (zh) 2019-01-01
HRP20211533T1 (hr) 2022-01-07
CO2019010578A2 (es) 2019-10-09
JP7159214B2 (ja) 2022-10-24
LT3625222T (lt) 2021-11-10
SG11201908729UA (en) 2019-10-30
EA201992676A1 (ru) 2020-05-06

Similar Documents

Publication Publication Date Title
MA49128A (fr) Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
MA49126A (fr) Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2
MA54169A (fr) Tolyles substitués utilisés en tant que fongicides
EP3356356A4 (fr) Composés utiles en tant que modulateurs de trpm8
DK3774791T3 (da) Heterocykliske forbindelser som immunmodulatorer
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
SI3743406T1 (sl) Modulatorji TMEM16A
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA55046A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
EP3328379A4 (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
IL281492A (en) Modulators of pnpla3 expression
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA47370A (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
DK3433234T3 (da) Allosteriske modulatorer af nicotinacetylcholinreceptorer
IL283967A (en) Modulators of hsd17b13 expression
EP3487839A4 (fr) Dérivés d'amide utilisés en tant que bloqueurs de nav1,7 et de nav1,8
EP3509588A4 (fr) Composés bicycliques utiles en tant que modulateurs du gpr120
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EP3654987A4 (fr) Utilisation de dérivés aminoalkylbenzothiazépine
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA42810A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EP2958564A4 (fr) Composés hétéro-aromatiques en tant que modulateurs de pi3 kinase
MA52286A (fr) Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine